GlassScriptPhysician profile
Zilla Huma Hussain
NPI 1528294154
$3,905.20
in general payments reported to CMS, 2019-2025
23 companies · $1,344 in 2025
The $1,344 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $146 · 2023: $1,615 · 2024: $800 · 2025: $1,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,721 · Travel and Lodging: $979 · Education: $58.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,721.46 |
| Travel and Lodging | $979.34 |
| Education | $58.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,178.07 | 2023 | Endoflip |
| Abbvie INC. | $689.71 | 2022-2025 | |
| Janssen Biotech, INC. | $399.49 | 2022-2025 | Tremfya, Stelara |
| Pfizer INC. | $249.52 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.06 | 2022-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $227.58 | 2023-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $168.23 | 2025 | |
| Ardelyx, INC. | $160.74 | 2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $90.97 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $88.80 | 2024-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $57.49 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $55.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $45.51 | 2024-2025 | |
| Lilly USA, LLC | $44.78 | 2025 | Omvoh |
| Celgene Corporation | $36.99 | 2022-2024 | Zeposia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $34.30 | 2023-2024 | Hanarostent Esophagus Tts(Ccc), Endoclot Phs |
| Aimmune Therapeutics, INC. | $34.02 | 2023 | |
| Celltrion USA INC. | $19.94 | 2024 | Zymfentra |
| Fresenius Kabi USA, LLC | $19.13 | 2024 | Idacio |
| Nestle Healthcare Nutrition INC. | $19.03 | 2023 | |
| Intercept Pharmaceuticals, INC. | $16.63 | 2023 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $14.87 | 2024 | Iqirvo |
| Merck Sharp & Dohme LLC | $14.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zilla Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.